Biotech · Private company
AsclepiX Therapeutics, Inc.
Track this companyFree. Adds AsclepiX Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials30 recruiting or active
Pipeline programs9From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline9
- AXT107 0.1 mgPhase 2 · Diabetic Macular Edema (DME)ClinicalTrials.gov · fetched Nov 12, 2026
- AXT107 0.1 mgPhase 2 · Neovascular Age-Related Macular Degeneration (nAMD)ClinicalTrials.gov · fetched Nov 12, 2026
- AXT107 0.25 mgPhase 2 · Diabetic Macular Edema (DME)ClinicalTrials.gov · fetched Nov 12, 2026
- AXT107 0.25 mgPhase 2 · Neovascular Age-Related Macular Degeneration (nAMD)ClinicalTrials.gov · fetched Nov 12, 2026
- AXT107 0.5 mgPhase 2 · Diabetic Macular Edema (DME)ClinicalTrials.gov · fetched Nov 12, 2026
- AXT107 0.5 mgPhase 2 · Neovascular Age-Related Macular Degeneration (nAMD)ClinicalTrials.gov · fetched Nov 12, 2026
- AXT107 High DosePhase 2 · Neovascular Age-related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- AXT107 Low DosePhase 2 · Neovascular Age-related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- AXT107 Mid DosePhase 2 · Neovascular Age-related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials3
- Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)PHASE1_PHASE2 · UNKNOWN · started Dec 19, 2023ClinicalTrials.gov NCT05859776 · fetched Nov 12, 2026
- Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular DegenerationPHASE1_PHASE2 · TERMINATED · started Feb 1, 2021ClinicalTrials.gov NCT04746963 · fetched Nov 12, 2026
- Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular EdemaPHASE1_PHASE2 · TERMINATED · started Dec 10, 2020ClinicalTrials.gov NCT04697758 · fetched Nov 12, 2026